"The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India," said G V Prasad, CEO Dr Reddy's in a statement.
At 2:59 pm, the stock was trading 3.9 per cent higher at Rs 4,618.75 per share as against 0.77 per cent rise in the S&P BSE Sensex.
India on Tuesday crossed the grim 5-million mark by recording 90,123 cases in the last 24-hours. With this, India is rapidly nearing the US tally of 6.7 million. The death toll has risen by 1,283 to 82,091.